Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | MTR | Q99707 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27595553 | 0.91 | MTTP (0.64) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6186544 | 0.90 | MTTP (0.72) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL1395278 | 0.89 | MTTP (0.80) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7157393 | 0.89 | MTTP (0.70) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL4787373 | 0.88 | MTTP (0.63) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL29355521 | 0.88 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL304604 | 0.88 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6191521 | 0.87 | MTTP (0.77) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6188141 | 0.86 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6603726 | 0.86 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951844-B2 | Phenyl naphthol ligands for thyroid hormone receptor | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | claimed |
| US-9796720-B2 | Imidazole-derived modulators of the glucocorticoid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-9593113-B2 | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160200728-A1 | IMIDAZOLE-DERIVED MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160185776-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2016059378-A1 | PARTICULATE PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS OF SAXAGLIPTIN AND METHODS FOR MAKING THE SAME | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | WO | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2044040-B1 | 1,3-OXAZOLE DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015027021-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-26 | — | — | WO | disclosed |
| EP-1024804-A4 | MTP INHIBITORS AND FAT SOLUBLE VITAMIN THERAPEUTIC COMBINATIONS TO LOWER SERUM LIPID LEVELS | BRISTOL MYERS SQUIBB CO (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1024804-A1 | MTP INHIBITORS AND FAT SOLUBLE VITAMIN THERAPEUTIC COMBINATIONS TO LOWER SERUM LIPID LEVELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-0989852-A1 | METHOD FOR TREATING ATHEROSCLEROSIS WITH AN MPT INHIBITOR AND CHOLESTEROL LOWERING DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0886637-A4 | — | — | 1998-12-30 | — | — | EP | disclosed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998050028-A1 | MTP INHIBITORS AND FAT SOLUBLE VITAMIN THERAPEUTIC COMBINATIONS TO LOWER SERUM LIPID LEVELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998031367-A1 | METHOD FOR TREATING ACID LIPASE DEFICIENCY DISEASES WITH AN MTP INHIBITOR AND CHOLESTEROL LOWERING DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1998031366-A1 | METHOD FOR TREATING ATHEROSCLEROSIS WITH AN MPT INHIBITOR AND CHOLESTEROL LOWERING DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1998031225-A1 | A METHOD OF INHIBITING OR TREATING PHYTOSTEROLEMIA WITH AN MTP INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200728-A1 | IMIDAZOLE-DERIVED MODULATORS OF THE GLUCOCORTICOID RECEPTOR | NFKBIA, NFRKB, NFKB1 | MTTP 1946/4885CHRM2 3560/4885ADRA2A 1584/4885 |
| US-20160185776-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | NFKBIA, IKBKB, NFRKB | MTTP 904/4885CHRM2 4374/4885ADRA2A 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.